An immunosuppressive peptide fraction was isolated by means of gel filtration, membrane partition, and ion exchange chromatography from the sera of patients hospi talized for cancer. The resulting peptide fraction, which was heterogeneous as judged by high-voltage electrophoresis, was found to suppress both phytohemagglutinin-induced proliferation of lymphocytes in vitro and the in vivo induction of splenic plaque-forming cells in mice. The specific activity of the peptide fraction, which was isolated from the sera of cancer patients, was significantly increased over that of the unfractionated starting material. Moreover, in control experiments, when the sera of normals or non-cancer-bearing hospitalized individuals were subjected to the same chromatographic techniques, no active peptide fraction could be obtained.
INTRODUCTION
For a number of years our laboratory has been involved in the isolation of an immunosuppressive peptide fraction from Cohn Fraction IV, derived from normal-human plasma, which we have called immunoregulatory a-globulin (17) . This peptide fraction has been shown to inhibit a number of T-cell-dependent immunological reactions in cluding delayed hypersensitivity responses, the rejection of transplantable tumors (2) , and the stimulation of peripheral blood lymphocytes by specific antigens and by PHA3 (1).
Since we have recently further demonstrated that a positive correlation exists between diminished delayed hypersensitiv ity responses and suppressive activity in the serum of cancer patients (15) , we decided to study the immunosuppressive sera of patients hospitalized with cancer to determine whether the immunological hyporeactivity of these patients was due to a peptide fraction similar to immunoregulatory a-globulin.
In this paper we describe the isolation, from small aliquots of sera of cancer patients, of a peptide fraction that 
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3 The abbreviation used is: PHA, phytohemagglutinin. ReceivedNovember 11, 1974; acceptedFebruary 28, 1975. possesses imniunosuppressive activity both in vitro and in vivo. Furthermore, when the same fractionation procedures were applied to the sera of normal volunteers or non-cancer bearing hospitalized patients, no immunosuppressive pep tide could be recovered.
MATERIALS AND METHODS
Collection of Sera. Aliquots of blood (30 ml) were collected from individual donors by peripheral venipunc ture. Following clot formation and clot retraction the serum was separated by centrifugation at 2000 x g for 30 mm. Sera were then either fractionated directly or immediately frozen and stored at â€"20Â°prior to usage.
Blood Donors. Cancer patients, ranging in age from 42 to 87 years, were all hospitalized individuals in whom the diagnosis of cancer was substantiated by tissue histology. Of the 3 males and 3 females studied, all had solid tumors and none were receiving chemotherapy or irradiation.
The normal group consisted of 3 males and 2 females and a poo1 of 12 individuals (4 males and 8 females) ranging in age from 23 to 37 years. These individuals were medical school personnel in good health.
As a further control, 28 patients who were hospitalized for routine surgical procedures were also studied. This group consisted of 15 males and 13 females ranging in age from 40 to 83 years and diagnosed as suffering from a wide range of chronic and acute noncancerous diseases.
Ion-Exchange Chromatography of the Sera of Cancer
Patients and Normal Individuals.Aliquots of human sera (10 ml), which were adjusted to pH 5.2 with 7% acetic acid ( Chemical Analyses. The polypeptide moiety was deter mined by the biuret procedure of MehI (13) utilizing bovine serum albumin as a standard. For the determination of the total neutral hexoses and sialic acid, the orcinol method of SÃ˜rensen and Haugaard (18) and the Warren technique (20) , respectively, were used. Lysozyme and a,-acid glyco protein served as references. The content of DNA and RNA was determined by the procedure of Dische (4). Cortisol was measured by the competitive protein-binding assay (16), RNase activity was assayed by the method of Kalnitsky et a!. (10) , and prostaglandin E, was determined by radioim munoassay after conversion to prostaglandin F1a (1 1).
Bioassay. The test for immunosuppressive activity mea sured inhibition of PHA-induced proliferation of human peripheral lymphocytes, a method described by us in previous publications (5, 6) . Human peripheral lymphocytes were obtained from the plasma after gravity sedimentation of heparinized blood at room temperature for 2 hr. The lymphocytes .were then purified on sterile cotton wool columns and eluted with Eagle's minimal essential medium (Grand Island Biological Co., Grand Island, N. Y.). After 3 washings the cells were counted and the viability determined with trypan blue dye in a hemocytometer chamber. The cells were generally 95% small lymphocytes and were 95% viable.
Tissue cultures were performed with 106 lymphocytes in 1 ml of Eagle's minimal essential medium containing addi tives. All tubes contained 10% fetal calf serum (from the same batch for all experiments), penicillin, streptomycin, and L-glutamine. All tubes except the unstimulated con trols contained 10 sg of PHA, a dose predetermined to
give optimal stimulation. Experimental tubes contained various concentrations of protein or peptide samples from cancer patients or from normal individuals. Additional control tubes contained a concentration of reference pooled normal human serum equal to the greatest concentration of experimental protein or peptide being tested. The refer ence serum has been used in all our experiments and, consistently, the counts in these tubes are equal to the counts of tubes that have no additional human serum added. The cultures were then maintained in stationary racks in a 5% CO2 humidifed environment at 37Â°for 48 hr. They were then pulsed by the addition of 4 sCi of [3H]thymidine for 16 to 18 hr. Before killing, viabilities were ascertained by trypan blue dye exclusion. Viabilities were equal in control and experimental groups. Following incubation the tubes were centrifuged, the cell pellets were washed 4 times with 2-ml aliquots of 0.9% NaCl solution, and finally they were dissolved in 1 ml of 0.01 N sodium hydroxide. To this were added 5 ml of a scintillation cock tail of dioxane, naphthalene, and PPO. Radioactivity was then counted in a Beckman scintillation counter.
All sera were initially tested for immunosuppressive activity at a 10% concentration of tissue culture. The extent of immunosuppressive activity was calculated as follows: Those sera that possessed significant activity, defined as 70% or greater suppression of PHA-induced DNA synthe sis, at the screening dose were chromatographed as de scribed above. Furthermore, the quantity of immunosup pressive activity for each of the fractions obtained after ion-exchange chromatography was expressed as â€oeunitsâ€• using the following calculation:
Immunosuppressive units = Total weight of pro tein fraction/smallest dose producing 100% sup pression of PHA stimulation in vitro
In vivo testing for immunosuppressive activity was per formed by a modification of the Jerne hemolytic plaque technique (19) . Adult CD-l mice (Charles River Breeding Laboratory, Wilmington, Mass.) were given i.p. injections of the protein or peptide to be tested 24 hr prior to immunization with approximately 4 x 108 sheep erythro cytes. These animals were sacrificed 4 days after immuniza tion and the number of plaques per spleen was determined (9). As a control, normal humanserumandhumanserum albumin, in concentrations equal to the greatest concentra tion of sample being tested, were used in all experiments.
RESULTS
In Vitro Assay for Immunosuppressive Activity. In order to obtain starting material for this study the sera of patients hospitalized with solid tissue cancer and those of normal volunteers were first tested for immunosuppression in vitro. Of the 53 cancer patients screened, 27 (50%) had im EFFLUENT VOLUME (ml) Chart 1. Ion-exchange chromatography of the sera obtained from normal and cancer patients on DEAE-cellulose. A flow rate of 10 ml/hr was used and 5-ml fractions were collected. A linear salt gradient Was establishedby the appropriatemixing of 250ml of 0.005Msodiumacetate, 
In markedcontrast, in vitro analysis of the fractions
obtained from the control groups demonstrated that there was no immunosuppressive activity in Fraction I (Table 2) . Furthermore, while the immunosuppressive activity of the control groups was also found in Peaks II, III, IV, and VI, the activity of these fractions was extremely low and the mean total immunosuppressive units of the normal donors and patients hospitalized for routine elective procedures were found to be only 8. 
Isolation of the Immunosuppressive Peptide Fractions.
Since Peak I, isolated from the sera of cancer patients, possessed the greatest amount of suppressive material, this 
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fraction was next subjected to ultrafiltration in order to determine whether its immunosuppressive activity was contained in a peptide fraction similar to immunoregulatory a-globulin isolated from normal human serum. Ultrafiltra tion of the major active fraction of cancer sera resulted in a significant decrease in the immunosuppressive activity of the retained high-molecular-weight proteins (Table 3 ). The protein fractions that were suppressive at doses ranging between 1 and 6 mg/mI prior to ultrafiltration, when assayed for inhibition of lymphocyte stimulation in vitro after ultrafiltration, were found to have little activity at doses that were initially active. Moreover, the fractions that passed through the filter were significantly suppressive at doses between 0. 1 and 0.3 mg/ml. In addition, in vivo analyses (Table 4 ) further demonstrated that the obtained peptide fractions were immunosuppressive in the intact mouse at a dose of 3.0 mg/mouse. 
In order to demonstrate that the immunosuppressive

Immunosuppressive
Peptide from Sera of Cancer Patients major amount of immunosuppressive activity of the sera of cancer patients was found in a fraction that appeared to be devoid of a-globulins. This protein fraction (DEAE-Peak I) was never active if isolated from the sera of non-cancer bearing individuals and, when isolated from cancer sera, possessed about 30 times niore activity than did the com bined active fractions of normal serum. In contrast, the suppressive activity contained in the sera of normal mdi viduals or those ill from nonmalignant diseases is ex tremely small in amounts and cannot be detected by in vitro assays prior to chromatographic procedures. How ever, after ion-exchange chromatography of the sera of control subjects, the activity was then found to reside in the a-globulin-rich fractions of their blood as judged by cellu lose acetate electrophoresis.
These protein fractions ac counted for all of the immunosuppressive activity found in control donors and represented less than 2% of the pro teins of their serum on a weight basis. The a-globulin-con taming peaks isolated from cancer sera were also immuno suppressive, although more so than in normal donors.
One might suggest that the immunosuppressive substance present in blood is initially carried by an a-globulin(s); however, as the suppressive compound increases in amount, as it seems to in some cancer patients, carrier sites become saturated and the active factor is then picked up by proteins that chromatograph in non-a-globulin containing fractions.
More important, however, was the finding that the immunosuppressive activity of the cancer sera used in this study could be removed from the high-molecular-weight protein fractions by ultrafiltration and that this activity is then contained in a low-molecular-weight peptide fraction. This peptide fraction was found to be readily dissociable from its protein carrier and would have been easily lost had conventional dialysis procedures been used in this study. Also, the active protein fractions isolated from normal donors or patients without cancer could not be subjected to the same ultrafiltration techniques because the amount and activity of material isolated from normal sera was too small to allow further investigation.
Furthermore, the peptide fraction isolated from the sera of patients with cancer closely resembles, both chemically and physicochemically, immunoregulatory a-globulin, an immunosuppressive peptide fraction that we have previously isolated in trace amounts from large pools of normal human blood (17) . Immunoregulatory a-globulin, like the peptide fraction isolated from cancer patients, has been shown to cross species barriers and is a peptide fraction that inhibits a wide variety of T-cell-mediated immune responses without affecting B-cell responses (2, 3, 12, 14) . We believe that immunoregulatory a-globulin may act biologically as a feedback regulator of cell-mediated immunity. If this is so, and if as has been shown in this study, immunoregulatory a-globulin or an immunoregulatory a-globulin-like peptide is synthesized in extremely large amounts in some cancer patients, then a high level of this circulating, naturally occurring immunosuppressive agent might be responsible for the failure of some cancer patients to mount an effective immune response against their tumors (7) . was not an artifact of preparation, Peak I from the normal group was subjected to the same chromatographic technique. The results (Tables 3 and 4) indicate that, although a peptide fraction could be isolated from this protein fraction, no detectable immunosuppressive activity could be identified. Chemical and Physicochemical Analyses. Chemical analy sis by the biuret procedure on the active low-molecular weight fraction, isolated from cancer patients, indicated that the total weight of this fraction could be accounted for by polypeptide. This finding was confiriped by the absence of neutral hexoses, sialic acid, cortisone, DNA, RNA, and prostaglandin E1. Furthermore, analyses for RNase activity demonstrated that this fraction possessed a negligible quantity of this enzyme.
On high-voltage electrophoresis the isolated active pep tide fraction was found to be heterogeneous, revealing ninhydrin-positive compounds with acidic, neutral, and basic electrophoretic characteristics (Chart 3). This fraction appeared to be similar electrophoretically to that isolated from pooled normal human plasma immunoregulatory a-globulin and the inactive peptide fraction isolated from a normal donor. + Chart 3. High-voltageelectrophoresisofthe immunosuppressive peptide fractions obtained from DEAE-Fraction I by ultrafiltration (CaS-P), from normal-human serum (NHS-P), and from Cohn Fraction IV (IRA-P). The latter 2 fractions appear to be similar electrophoretically to the active peptide fraction isolated from the sera of cancer patients.
Arginine (R), lysine (K), glycine (G), and aspartic acid (D) served as references.
DISCUSSION
Although it is well known that there is a generalized depression of cellular immunity in some individuals afflicted with cancer, little information is available to explain this important immunological phenomenon. In order better to understand these findings and because we have recently
shown that 66% of the sera of cancer patients who lacked delayed hypersensitivity responsiveness are capable of inhib iting PHA stimulation of normal lymphocytes (15), we decided to study the immunosuppressive sera of cancer patients in order to determine what might account for these potentially significant observations.
